Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

NOAC

- PMLiVE

AstraZeneca’s Imfinzi regimen receives positive CHMP opinion for early gastric and gastroesophageal cancer

Gastric cancer is the fifth highest cause of cancer deaths worldwide, with almost a million people diagnosed annually

- PMLiVE

Sanofi’s Rezurock receives positive CHMP opinion for chronic graft-versus-host disease

Up to 50% of allogeneic haematopoietic stem cell transplant patients develop chronic GVHD

- PMLiVE

Roche’s Lunsumio receives positive CHMP opinion for follicular lymphoma

The recommendation for the subcutaneous formulation follows encouraging trial data

- PMLiVE

CHMP recommends BeOne Medicines’ Tevimbra for new lung cancer indication

Non-small cell lung cancer accounts for up to 90% of all lung cancer cases

- PMLiVE

Eli Lilly’s Alzheimer’s disease drug donanemab recommended by CHMP

Up to 6.9 million people in Europe are affected by the neurodegenerative disorder

- PMLiVE

Moderna’s LP.8.1-adapted COVID-19 vaccine recommended by CHMP

Global health authorities have recommended that vaccines for the 2025-2026 season should target LP.8.1

- PMLiVE

CHMP recommends tablet formulation of BeOne’s targeted cancer drug Brukinsa

The new formulation would allow blood cancer patients to halve their daily pill intake

- PMLiVE

Sanofi’s Sarclisa recommended by CHMP for new multiple myeloma indication

Around 46,000 cases of the disease are expected to be diagnosed in Europe this year

- PMLiVE

Ipsen receives CHMP recommendation for Cabometyx in neuroendocrine tumours

The number of patients newly diagnosed with NETs is believed to be on the rise

- PMLiVE

AstraZeneca receives CHMP recommendation for Imfinzi regimen in bladder cancer

More than 614,000 cases of bladder cancer are diagnosed globally every year

- PMLiVE

AstraZeneca’s Calquence regimens recommended by CHMP for chronic lymphocytic leukaemia

It is hoped that the fixed-duration treatments will reduce the risk of adverse events and drug resistance

- PMLiVE

Takeda receives CHMP recommendation for Adcetris in Hodgkin lymphoma

The EC will review the committee’s positive opinion as it makes a decision on Adcetris in this indication

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links